SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2) inhibitors proved efficacious for people with heart failure regardless of the presence of type 2 diabetes (Zou et al., 2024; Zou et al., 2022).